Meropenem: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy

Drugs

Volumn 50, Issue 1, 1995, Pages 73-101

  Wiseman, Lynda R ^a   Wagstaff, Antona J ^a   Brogden, Rex N ^a   Bryson, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYLASE; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG STABILITY; EOSINOPHILIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC INFECTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MENINGITIS; NAUSEA; NEUTROPENIA; NONHUMAN; POSTANTIBIOTIC EFFECT; REVIEW; SEIZURE; SEPTICEMIA; SKIN INFECTION; THROMBOCYTOSIS; URINARY TRACT INFECTION; VOMITING;

ABSORPTION; AGING; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMAN; THIENAMYCINS; TISSUE DISTRIBUTION;

EID: 0029060787     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550010-00007     Document Type: Article

References (195)

1. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex
2. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I
3. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes
4. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect against staphylococci
5. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus
6. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium
7. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic [in Japanese]
8. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic
9. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide
10. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex
11. vitro studies of meropenem
12. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom
13. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs
14. Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent
15. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants
16. In-vitro activity of meropenem, imipenem, the penem HRE 664 and ceftazidime against clinical isolates from West Germany
17. In vitro antibacterial activity of meropenem [in Japanese]
18. Multicenter in vitro evaluation of SM-7338, a new carbapenem
19. Bacteriological and clinical studies on meropenem [in Japanese]
20. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy
21. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338
22. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I
23. In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338
24. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338)
25. In vitro activity of L-627, a new carbapenem
26. In vitro activity of a catechol-substituted cephalosporin, GR69153
27. Comparative in-vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin
28. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with beta-lactamase- and non-enzyme-mediated resistance to ampicillin
29. In-vitro activity of meropenem against clinical isolates obtained in Canada
30. Laboratory and clinical studies on meropenem [in Japanese]
31. Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates
32. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates
33. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials
34. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, cotrimoxazole, and ciprofloxacin against Pseudomonas cepacia
35. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases
36. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactarns, chloramphenicol and ciprofloxacin
37. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli
38. Activity of meropenem, against gram-positive bacteria
39. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics
40. In-vitro antimicrobial susceptibility of Rhodococcus equi
41. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp
42. The growth-inhibitory properties of meropenem against anaerobes of clinical importance
43. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers
44. Meropenem: in-vitro activity and kinetics against organisms of the Bacteroides fragilis group
45. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes
46. Susceptibility of anaerobic bacteria to meropenem
47. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates
48. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents
49. L-627, a novel carbapenem: in-vitro activity against anaerobes
50. In vitro activity of L-627 against anaerobic bacteria
51. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole
52. Bactericidal activity of meropenem and interactions with other antibiotics
53. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria
54. Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams
55. Antibacterial effects of meropenem and imipenem against Haemophilus influenzae
56. Bactericidal activity of meropenem against Pseudomonas aeruginosa
57. Antibacterial effect of meropenem and imipenem on Proteus mirabilis
58. Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance
59. In vitro activities of 15 oral β-lactams against Klebsiella pneumoniae harboring new extended-spectrum β-lactamases
60. Interactions of meropenem with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins
61. Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen
62. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases
63. Susceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamases
64. Comparative stability of meropenem against beta-lactamases from Bacteroides spp
65. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms
66. Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics
67. Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci
68. The antibacterial activity of meropenem in combination with gentamicin or vancomycin
69. In vitro studies of combinations of piperacillin and various antimicrobial agents on MRSA [in Japanese]
70. Comparison of methodologies used in assessing the postantibiotic effect
71. A comparison of the in vitro post-antibiotic effect of meropenem and imipenem versus selected enterobacteriaceae and other pathogens
72. In vitro and in vivo postantibiotic effect of meropenem [in Japanese]
73. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem
74. The postantibiotic effect of meropenem and imipenem against selected bacteria
75. In-vivo and in-vitro study of the postantibiotic effect of meropenem
76. Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods
77. Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems [letter]
78. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa
79. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa
80. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa
81. Mechanisms of resistance to β-lactam antibiotics
82. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities
83. Permeability of the outer membrane of Moraxella catarrhalis for β-lactam antibiotics
84. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins
85. Role of 0mpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa
86. Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy
87. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa
88. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem
89. Prevention of drug access to bacterial targets: permeability barriers and active efflux
90. Role of efflux pump (s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin
91. Nosocomial outbreak of meropenem resistant Pseudomonas aeruginosa infections in a cancer centre [letter]
92. Interaction between human monocytes and penicillin G in relation to the antibacterial effect on Staphylococcus aureus
93. Effect of penicillin G on Staphylococcus aureus phagocytosed by human monocytes
94. The entry of meropenem into human macrophages and its immunomodulating activity
95. Interaction of meropenem with humoral and phagocytic defences
96. Intracellular bactericidal activities of cefpirome and meropenem as compared with ciprofloxacin against Serratia marcescens
97. Therapeutic activity of meropenem in experimental infections
98. The pharmacokinetics of meropenem in volunteers
99. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem
100. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men
101. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young healthy males
102. Meropenem pharmacokinetics and penetration into an inflammatory exudate
103. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment
104. The pharmacokinetics of meropenem
105. A study of penetration of meropenem into bile using endoscopic retrograde cholangio-graphy
106. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion
107. Investigation of meropenem levels in the human bone marrow blood, bone, joint fluid and joint tissues [in Japanese]
108. Concentration of meropenem in serum and in bronchial secretions in’ patients undergoing fibreoptic bronchoscopy
109. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges
110. Basic and clinical studies on meropenem in obstetrics and gynecology [in Japanese]
111. Pharmacokinetic and clinical studies of meropenem in the field of obstetrics and gynecology [in Japanese]
112. Pharmacokinetic and clinical studies of meropenem in the field of obstetrics and gynecology [in Japanese]
113. Laboratory and clinical studies on meropenem [in Japanese]
114. Basic and clinical studies on meropenem in ophthalmology [in Japanese]
115. Concentration of meropenem in tissues and clinical efficacy in otorhinolaryngology [in Japanese]
116. The disposition and metabolic fate of 14C-meropenem in man
117. Pharmacokinetic and clinical studies with meropenem in the pediatric field [in Japanese]
118. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease
119. Pharmacokinetics of meropenem in subjects with renal insufficiency
120. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment
121. Antibiotics and the abdomen
122. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. Report from a Swedish Study Group
123. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery
124. Carbapenems reduce hospital stay for perforated & gangrenous appendicitis compared with clindamycin/aminoglycoside [abstract]
125. Acute Meningitis
126. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
127. Is there a place for carbapenems in the therapy of meningitis
128. Efficacy and safety of meropenem in the treatment of meningitis
129. High-dose meropenem in meningitis due to Pseudomonas aeruginosa
130. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa
131. A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia [in Japanese]
132. A comparative study of meropenem and imipenem/cilastatin sodium in chronic respiratory tract infections [in Japanese]
133. Dose-finding study on meropenem in bacterial pneumonia [in Japanese]
134. Meropenem versus imipenem: relationship between microbiological parameters and clinical outcome in lower respiratory tract infections
135. Clinical evaluation of meropenem for the treatment of complicated urinary tract infections–a double-blind controlled study using imipenem/cilastatin
136. Dose finding study of meropenem in complicated urinary tract infection [in Japanese]
137. Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems
138. Meropenem in abdominal skin and soft tissue infections in the field of surgery [in Japanese]
139. Skin tissue concentration and clinical evaluation of meropenem [in Japanese]
140. Meropenem versus imipenem/cilastatin in the treatment of hospitalised patients with skin and soft tissue infections
141. Basic and clinical studies of meropenem in obstetrics and gynecology [in Japanese]
142. Clinical study of SM-7338 in obstetrics and gynecology [in Japanese]
143. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
144. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem
145. Effect of meropenem on the intestinal microflora
146. Meropenem: evidence of lack of proconvulsive tendency in mice
147. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats
148. Imipenem/cilastatin treatment of bacterial meningitis in children
149. Clinically important aspects of carbapenem safety